Rapport Therapeutics, Inc. (RAPP) saw its stock price drop sharply by 5.17% during Thursday's intraday trading session.
The decline appears to be driven by analyst insights on the company released earlier in the day. While the broader healthcare sector was viewed optimistically, the specific reports concerning Rapport Therapeutics likely contained negative sentiment or downgrades, prompting the sell-off.